Maximum quantity allowed is 999
Please select the quantity
CAS RN: 51333-22-3 | Product Number: B3909
Budesonide
×
![]()
×
Purity: >98.0%(HPLC)
Synonyms:
- (+)-16α,17α-Butylidenedioxy-11β,21-dihydroxy-1,4-pregnadiene-3,20-dione
Documents:
| Size | Unit Price | Belgium | Japan* | Quantity |
|---|---|---|---|---|
| 200MG |
£33.00
|
Contact Us | ≥20 |
|
| 1G |
£112.00
|
Contact Us | ≥20 |
|
*Stock available in Belgium will be delivered in 1 to 3 days
*Stock available in Japan will be delivered in 1 to 2 weeks (excludes regulated items and dry ice shipments).
Specifications
| Appearance | White to Light yellow powder to crystal |
| Purity(HPLC) | min. 98.0 % (total of isomers) |
| Elemental analysis(Carbon) | 68.00 to 71.00 % |
| Specific rotation [a]20/D | +100 to +110 deg(C=0.28、CH2Cl2) |
Properties (reference)
| Specific Rotation | 105° (C=0.28,CH2Cl2) |
| Solubility in water | Insoluble |
| Solubility (soluble in) | Chloroform,Methanol |
| Solubility (slightly sol. in) | Acetone,Ethanol |
| Solubility (very slightly) | Ether,dichloromethane |
GHS
| Pictogram |
|
| Signal Word | Warning |
| Hazard Statements | H315 : Causes skin irritation. |
| Precautionary Statements | P264 : Wash skin thoroughly after handling. P280 : Wear protective gloves. P302 + P352 : IF ON SKIN: Wash with plenty of water. P362 + P364 : Take off contaminated clothing and wash it before reuse. P332 + P313 : If skin irritation occurs: Get medical advice/ attention. |
Related Laws:
| EC Number | 257-139-7 |
| RTECS# | TU3723000 |
Transport Information:
| HS Number | 2937290000 |
Application
Budesonide: A Potent Glucocorticoid Receptor Antagonist
Budesonide is an anti-inflammatory corticosteroid that exhibits potent glucocorticoid activity and weak mineralocorticoid activity.1-6） Budesonide has a strong affinity for glucocorticoid receptor, and it is reported that budesonide has approximately 8.5-fold, 15-fold, and 195-fold greater than those of dexamethasone [D1961], prednisolone [P0637], and hydrocortisone [H0533], respectively.6) Budesonide is mainly metabolized by CYP3A4.6) (The product is for research purpose only.)
References
- 1)Scientific rationale for inhaled combination therapy with long-acting β2-agonists and corticosteroids(a review)
- 2)Budesonide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in asthma and rhinitis(a review)
- 3)Budesonide: A review of its pharmacological properties and therapeutic efficacy in inflammatory bowel disease(a review)
- 4)Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease(a review)
- 5)Treatment of inflammatory bowel disease: a review of medical therapy(a review)
- 6)Budesonide Multi-matrix for the Treatment of Patients with Ulcerative Colitis (a review)
PubMed Literature
Articles/Brochures
TCIMAIL
Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number is entered
Analytical Charts
Please enter Lot Number
Incorrect Lot Number is entered
The requested analytical chart is not available. Sorry for the inconvenience.